Feline calicivirus and other respiratory pathogens in cats with Feline calicivirus-related symptoms and in clinically healthy cats in Switzerland

Berger, Alice Sophie

Abstract: Background: Cats with feline calicivirus (FCV)-related symptoms are commonly presented to veterinary practitioners. Various clinical manifestations have been attributed to FCV, i.e. upper respiratory tract disease (URTD), oral ulcerations, gingivostomatitis, limping syndrome and virulent systemic disease. Additionally, healthy cats can shed FCV. The aims of this study were 1) to investigate the frequency of FCV in cats with FCV-related symptoms and in healthy cats in Switzerland, 2) to assess risk and protective factors for infection, such as signalment, housing conditions, vaccination, and co-infection with URTD-associated pathogens, and 3) to address the association between clinical symptoms and FCV infection. Results: Oropharyngeal, nasal and conjunctival swabs were collected in 24 veterinary practices from 200 FCV-suspect and 100 healthy cats originating from 19 cantons of Switzerland. The samples were tested for FCV using virus isolation and reverse-transcription real-time quantitative polymerase chain reaction (qPCR) and for feline herpesvirus-1 (FHV-1), Mycoplasma felis, Chlamydophila felis, Bordetella bronchiseptica using real-time qPCR. Within the two populations (FCV-suspect/healthy), the observed PCR prevalences were: FCV 45%/8%, FHV-1 20%/9%, C. felis 8%/1%, B. bronchiseptica 4%/2%, M. felis 47%/31% and any coinfections thereof 40%/14%. Based on multivariable regression models amongst FCV-suspect cats (odds ratio [95% confidence interval]), co-infection with M. felis (1.75 [0.97; 3.14], group housing (2.11 [1.02; 4.34]) and intact reproductive status (1.8 [0.99; 3.28]) were found to be risk factors for FCV infection. In healthy cats, intact reproductive status (22 [1.85; 266.7]) and group housing (46.4 [5.7; 377.7]) were found to be associated with FCV infection. Based on an univariable approach, FCV-suspect cats were found to be significantly less often FCV-positive when vaccinated (0.48 [0.24; 0.94]. Oral ulcerations, salivation, gingivitis and stomatitis, but not classical signs of URTD were significantly associated with FCV infection (all p<0.001). Conclusions: FCV was detected in less than half of the cats that were judged FCV-suspect by veterinary practitioners. For a clinical diagnosis, FCV-related symptoms should be revisited. FCV infection was present in some healthy cats, underlining the importance of asymptomatic carriers in FCV epidemiology. To reduce FCV-related problems in multi-cat environments, reduction of group size in addition to the generally recommended vaccination are advocated.

Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: [https://doi.org/10.5167/uzh-122861]
Dissertation
Accepted Version

Originally published at:
Berger, Alice Sophie. Feline calicivirus and other respiratory pathogens in cats with Feline calicivirus-related symptoms and in clinically healthy cats in Switzerland. 2015, University of Zurich, Vetsuisse Faculty.
Departement für Nutztiere
der Vetsuisse-Fakultät Universitäts Zürich
Direktor: Prof. Dr. med. vet. Dr. med. vet. h.c. Ueli Braun

Veterinärmedizinisches Labor
Leiterin: Prof. Dr. med. vet. Regina Hofmann-Lehmann

**Feline calicivirus and other respiratory pathogens in cats with Feline calicivirus-related symptoms and in clinically healthy cats in Switzerland**

**Inaugural-Dissertation**

zur Erlangung der Doktorwürde der
Vetsuisse-Fakultät Universität Zürich

vorgelegt von

**Alice Sophie Berger**

Tierärztin
von Oberbuchsitten und Subingen, SO

genehmigt auf Antrag von

Prof. Dr. med. vet. Regina Hofmann-Lehmann, Referentin

2015
# Table of Contents

**ZUSAMMENFASSUNG** .................................................................................................................. 2  
**SUMMARY** ............................................................................................................................... 3  
**FELINE CALICIVIRUS AND OTHER RESPIRATORY PATHOGENS IN CATS WITH**  
**FELINE CALICIVIRUS-RELATED SYMPTOMS AND IN CLINICALLY HEALTHY**  
**CATS IN SWITZERLAND** ............................................................................................................ 4  
**ABSTRACT** ..................................................................................................................................... 5  
**BACKGROUND** .......................................................................................................................... 6  
**MATERIAL AND METHODS** ....................................................................................................... 8  
  - Cats ............................................................................................................................................... 8  
  - Sample collection and analysis ................................................................................................... 10  
  - Sample processing and total nucleic acid (TNA) extraction ......................................................... 11  
  - Virus isolation ............................................................................................................................. 11  
  - Real-time qPCR and RT-qPCR assays ....................................................................................... 12  
  - Statistical analysis ...................................................................................................................... 13  
**RESULTS** ...................................................................................................................................... 14  
**DISCUSSION** ................................................................................................................................ 17  
**CONCLUSION** ............................................................................................................................. 22  
**LIST OF ABBREVIATIONS** .......................................................................................................... 23  
**COMPETING INTERESTS** ............................................................................................................ 23  
**AUTHORS’ CONTRIBUTIONS** ..................................................................................................... 23  
**ACKNOWLEDGEMENTS** ............................................................................................................. 23  
**REFERENCES** .............................................................................................................................. 24  
**TABLES** ....................................................................................................................................... 34  
**FIGURES** ....................................................................................................................................... 38  
**ADDITIONAL FILES** .................................................................................................................... 41
Zusammenfassung

Das feline Calicivirus (FCV) ist ein bedeutsames, weltweit vorkommendes RNA-Virus. FCV-Infektionen sind mit oralen Ulzera und oberen Atemwegserkrankungen (OAWE) assoziiert, aber auch hochvirulente FCV Stämme mit tödlichem Krankheitsverlauf wurden beschrieben. Ziele der Studie waren es, die Häufigkeit einer FCV-Infektion bei Katzen mit FCV-assoziierten Symptomen und klinisch gesunden Katzen zu untersuchen; Risiko- und protektive Faktoren wie Signalement, Haltung, Impfstatus und Ko-Infektionen mit OAWE-assoziierten Pathogenen und die Assoziation zwischen FCV-Infektion und klinischen Symptomen zu erfassen. Oropharyngeale Zytobrush, nasale und konjunktivale Tupfer wurden von 200 Katzen mit FCV-Infektionsverdacht anhand von klinischen Symptomen und 100 klinisch gesunden Katzen in der Schweiz gesammelt. Die Proben wurden mit Virusisolation und RT-qPCR auf FCV und mit qPCR auf felines Herpesvirus-1 (FHV-1), Chlamydophila felis, Mycoplasma felis und Bordetella bronchiseptica untersucht. Die Prävalenzen (FCV-Verdacht/gesund) waren: FCV 45%/8%, FHV-1 20%/9%, C. felis 8%/1%, B. bronchiseptica 4%/2%, M. felis 47%/31%. Geimpfte Katzen waren seltener FCV-positiv als nicht geimpfte. Ko-Infektion mit M. felis, intakter Reproduktionsstatus und Gruppenhaltung waren Risikofaktoren für die FCV-Infektion. FCV-Positivität war mit Gingivostomatitis und oralen Ulzera assoziiert, aber nicht mit Symptomen der OAWE. Kleine Katzengruppen und Impfung werden zum Schutz vor FCV Infektionen empfohlen.

Stichworte: Felines Calicivirus, Risikofaktoren, Impfung, obere Atemwegserkrankung, Gingivostomatitis
Summary

Feline calicivirus (FCV) is an important RNA virus in felids. Infected cats typically show oral cavity lesions and upper respiratory tract disease (URTD), whereas virulent strains of FCV have been associated with fatal disease. The aims of this study were to investigate the frequency of FCV in cats with FCV-related symptoms and in healthy cats in Switzerland, to assess risk and protective factors for infection, such as signalment, housing conditions, vaccination, and co-infection with URTD-associated pathogens, and to address the association between clinical symptoms and FCV infection. Oropharyngeal cytobrushes, nasal and conjunctival swabs were collected from 200 FCV-suspect and 100 healthy cats in Switzerland. Samples were analyzed for FCV by virus isolation and RT-qPCR. For feline herpesvirus-1 (FHV-1), *Mycoplasma felis, Chlamydophila felis, Bordetella bronchiseptica* qPCR was performed. The prevalences within the two populations (FCV-suspect/healthy) were: FCV 45%/8%, FHV-1 20%/9%, *C. felis* 8%/1%, *B. bronchiseptica* 4%/2%, *M. felis* 47%/31%. Vaccinated cats were less frequently FCV-positive than unvaccinated cats. Co-infection with *M. felis*, group housing and intact reproductive status were found to be risk factors for FCV infection. FCV was associated with gingivostomatitis and oral ulceration, but not with URTD. To reduce FCV-related problems reduction of group size in addition to the generally recommended vaccination are suggested.

Keywords: feline calicivirus, risk factors, vaccination, upper respiratory tract disease, gingivostomatitis
Feline calicivirus and other respiratory pathogens in cats with Feline calicivirus-related symptoms and in clinically healthy cats in Switzerland

Alice Berger1*, Barbara Willi1,2*, Marina L. Meli1,3, Felicitas S. Boretti2, Sonja Hartnack4, Anou Dreyfus4, Hans Lutz1, Regina Hofmann-Lehmann1,3§

1Clinical Laboratory, 2Clinic for Small Animal Internal Medicine, 3Center for Clinical Studies, 4Section of Epidemiology, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland

*These authors contributed equally to the study.

§Corresponding author

Mailing address: Clinical Laboratory, Vetsuisse Faculty, University of Zurich, Winterthurerstr. 260, 8057 Zurich, Switzerland. Phone: +41 44 635 83 11. Fax: +41 44 635 89 23. E-mail: rhofmann@vetclinics.uzh.ch

E-mail addresses:

AB: aberger@vetclinics.uzh.ch
BW: bwilli@vetclinics.uzh.ch
MLM: mmeli@vetclinics.uzh.ch
FSB: fboretti@vetclinics.uzh.ch
SH: sonja.hartnack@access.uzh.ch
AD: adreyfus@vetclinics.uzh.ch
HL: hlutz@vetclinics.uzh.ch
RHL: rhofmann@vetclinics.uzh.ch
Abstract

Background: Cats with feline calicivirus (FCV)-related symptoms are commonly presented to veterinary practitioners. Various clinical manifestations have been attributed to FCV, i.e. upper respiratory tract disease (URTD), oral ulcerations, gingivostomatitis, limping syndrome and virulent systemic disease. Additionally, healthy cats can shed FCV. The aims of this study were 1) to investigate the frequency of FCV in cats with FCV-related symptoms and in healthy cats in Switzerland, 2) to assess risk and protective factors for infection, such as signalment, housing conditions, vaccination, and co-infection with URTD-associated pathogens, and 3) to address the association between clinical symptoms and FCV infection.

Results: Oropharyngeal, nasal and conjunctival swabs were collected in 24 veterinary practices from 200 FCV-suspect and 100 healthy cats originating from 19 cantons of Switzerland. The samples were tested for FCV using virus isolation and reverse-transcription real-time quantitative polymerase chain reaction (qPCR) and for feline herpesvirus-1 (FHV-1), Mycoplasma felis, Chlamydophila felis, Bordetella bronchiseptica using real-time qPCR. Within the two populations (FCV-suspect/healthy), the observed PCR prevalences were: FCV 45%/8%, FHV-1 20%/9%, C. felis 8%/1%, B. bronchiseptica 4%/2%, M. felis 47%/31% and any co-infections thereof 40%/14%. Based on multivariable regression models amongst FCV-suspect cats (odds ratio [95% confidence interval]), co-infection with M. felis (1.75 [0.97; 3.14], group housing (2.11 [1.02; 4.34]) and intact reproductive status (1.8 [0.99; 3.28]) were found to be risk factors for FCV infection. In healthy cats, intact reproductive status (22 [1.85; 266.7]) and group housing (46.4 [5.7; 377.7]) were found to be associated with FCV infection. Based on an univariable approach, FCV-suspect cats were found to be significantly less often FCV-positive when vaccinated (0.48 [0.24; 0.94]. Oral ulcerations, salivation, gingivitis and stomatitis, but
not classical signs of URTD were significantly associated with FCV infection (all p<0.001).

**Conclusions:** FCV was detected in less than half of the cats that were judged FCV-suspect by veterinary practitioners. For a clinical diagnosis, FCV-related symptoms should be revisited. FCV infection was present in some healthy cats, underlining the importance of asymptomatic carriers in FCV epidemiology. To reduce FCV-related problems in multi-cat environments, reduction of group size in addition to the generally recommended vaccination are advocated.

**Keywords:** Feline calicivirus, feline herpesvirus-1, *Mycoplasma felis, Chlamydophila felis*, risk factors, vaccination, upper respiratory tract disease, gingivostomatitis, oral ulcerations, multivariable analysis

**Background**

Feline calicivirus (FCV) is a RNA virus that occurs worldwide in domestic cats and exotic felids [1, 2]. FCV infections are commonly associated with oral ulcerations and salivation [3, 4]. Other clinical syndromes that have been attributed to FCV infection include chronic stomatitis [3, 5] and a limping syndrome [6-8]. Some years ago, highly virulent systemic FCV infections associated with fatal disease have been reported in several countries, initially in North America [9, 10] and subsequently in Europe [11-13]. Outbreaks of severe FCV infections associated with edema and skin ulcerations have also been described in cats in Switzerland (Willi et al., submitted for publication).

FCV has also been assigned to the upper respiratory tract disease (URTD) complex ('cat flu') [14-17]. In addition to FCV, at least four other pathogens have been shown to be associated with this syndrome, including feline herpesvirus type 1 (FHV-1),
Mycoplasma felis, Chlamydophila felis and Bordetella bronchiseptica [14, 16, 18-24]. Cats with URTD are commonly presented to veterinary practitioners and show symptoms such as lethargy, pyrexia, anorexia, sneezing, nasal discharge, ocular discharge, conjunctivitis and keratitis [14, 19].

Conventional, nested and real-time reverse-transcriptase quantitative polymerase chain reaction (RT-qPCR) assays have been developed to amplify FCV-specific RNA from clinical specimens [25-29]. The high genetic variability of FCV can hamper the diagnostic sensitivity of FCV-specific molecular assays [2]. Virus isolation has been advocated as an alternative diagnostic tool, but this method is not routinely available [2]. Virus isolation is less sensitive to genomic variation, but the method might fail due to virus inactivation during transport, thus resulting in reduced diagnostic sensitivity [2].

FCV vaccines have been shown to be efficacious in protecting cats from the development of severe disease; however, they do not induce sterilizing immunity [30, 31]. Moreover, most commercially available vaccines have been based on only a few FCV strains (i.e. FCV F9 and 255) for many decades. Therefore, the protective potential of FCV vaccines against different circulating FCV isolates has been controversially discussed in recent years [32-35]. Efforts are made for the identification of new vaccine strains with broader cross-reactivity, the development of bi- or polyvalent vaccines and the inclusion of local FCV isolates [35-38]. Along these lines, a vaccine containing two novel FCV strains has become commercially available in Switzerland (FCV G1 and 431) [35, 36].

Despite the introduction of FCV vaccines several decades ago, cats with FCV-related symptoms are still commonly presented in veterinary practices. A presumptive clinical diagnosis relies on the presence of FCV-related symptoms [2]. However, clinical
signs induced by FCV and other URTD-associated pathogens can overlap and co-infections are common [4, 14-17]. Molecular assays to detect URTD-associated pathogens in clinical specimens might aid the diagnosis. Because asymptomatic carriers have been reported, results of molecular assays must be interpreted together with clinical presentation.

The aims of this study were to investigate the frequency of FCV in cats suspected FCV positive by veterinary practitioners and in clinically healthy cats in Switzerland, and to address potential risk and protective factors for infection in both groups of cats, such as signalment, housing conditions, vaccination, and co-infection with URTD-associated pathogens. Furthermore, the association between a number of different clinical symptoms and FCV infection was assessed.

**Material and Methods**

**Cats**

A total of 200 clinically diseased cats with symptoms compatible with FCV infection (FCV-suspect cats) and 100 clinically healthy cats were enrolled. The study was part of a large FCV project with the goal to obtain a collection of FCV isolates from symptomatic and asymptomatic cats in Switzerland for genetic and serological studies. Both populations were sampled by veterinary surgeons in Switzerland between September 2012 and April 2013. The goal was to include samples originating from 20 randomly selected veterinary practices in 17 different geographic regions (cantons) of Switzerland (ten FCV-suspect and five healthy cats per practice). Only one cat per owner (e.g., same household, cattery) was included. The veterinarians did get informed consent from the cat owners. All samples were taken as part of a diagnostic workup or for routine testing of FeLV/FIV in healthy cats and all results were provided to the veterinarians and the cat owners; no ethical approval
was necessary for this study in compliance with Swiss regulations [39]. Veterinary practices that were not able to collect a sufficient number of samples within the given time frame (eight months) were supported by a second or third veterinary practice within the same canton. This resulted in the participation of 24 veterinary practices in 17 cantons and the enrollment of 300 cats originating from 19 out of 26 cantons in Switzerland (Figure 1).

The participating veterinarians were provided with a list of the following FCV-related clinical signs: sneezing, nasal and/or ocular discharge, conjunctivitis, caudal stomatitis, chronic stomatitis and/or gingivitis, lingual and/or oral ulceration, pneumonia, shifting lameness, or a combination of fever, cutaneous edema and dermal ulceration of the face and/or limbs. The clinical signs were selected based on the guidelines on feline calicivirus infection by the European Advisory Board on Cat Diseases (ABCD) and recent publications [2, 40]. The written instructions contained illustrations on how to recognize FCV-associated clinical signs, as described above, and how to collect and ship the samples. Inclusion criteria for clinically healthy cats were the absence of any clinical signs based on anamnesis and clinical examination of the participating veterinarian. Cats that had been vaccinated against FCV, FHV-1 or *C. felis* within 21 days prior to the sample collection or that were younger than eight weeks were excluded.

To record demographic data for each enrolled animal, the veterinarians filled out a questionnaire during the cat’s visit at the clinic. To avoid interviewer bias, the participating veterinarians received written instructions on how to fill in the questionnaire. A similar questionnaire has been used in earlier studies [41, 42]. The questionnaire was comprised of different sections on geographic data (address of cat owner), demographic data (age, sex, reproductive status, breed of the cat), husbandry data (type of husbandry, such as private home, farm, cat breeder, feral
cat and cattery, number of cats per household, outdoor access, contact to dogs with kennel cough), data on vaccine history according to the clinical record and vaccination card (vaccination status for FCV/FHV-1/feline parvovirus, date of primary immunization, booster immunizations, vaccines used, vaccination status for feline leukemia virus (FeLV), date of the last FeLV vaccination), retrovirus status (FeLV and/or feline immunodeficiency virus (FIV) test results and date of testing), data on medical history (antiviral, antibiotic and immunosuppressive treatment at the time of sample collection and up to two months before collection) and results of the clinical examination.

**Sample collection and analysis**

An oropharyngeal cytobrush, as well as a nasal and a conjunctival cotton swab were collected from each cat. Sample collection material was provided by the investigators. Conjunctival swabs were collected prior to any diagnostic treatment, such as fluorescein application. Each cytobrush and swab was placed in a sterile Safe-Lock Eppendorf tube containing 300 µl of sterile viral transport medium. The medium consisted of 200 ml bi-distilled sterile water, 4 ml HEPES-Buffer 1 M (SIGMA-ALDRICH CHEMIE GmbH, Steinheim, Germany), 25 ml Dulbecco’s MEM 10x (Biochrom, Berlin, Germany), 25 ml heat inactivated fetal calf serum (Charge DO2303P, Origin South America, Bio Concept, Allschwil, Switzerland), 3 ml 100 x Antibiotic-Antimycotic (Gibco, Life Technologies) and 4 ml sodium hydrogen bicarbonate 7.5% (Merck, Darmstadt, Germany) at a pH of 7 that was adjusted using 1 M sodium hydroxide (Merck). Samples were stored at 4°C prior to shipping to the laboratory by priority mail. All samples were processed within 96 hours after collection.
**Sample processing and total nucleic acid (TNA) extraction**

Upon arrival, the cytobrushes and swabs were incubated at 40°C for 10 minutes. The cytobrushes and swabs were then turned upside down and centrifuged for 1 minute at 6,440 x g. The samples from each patient (oropharyngeal cytobrush and nasal and conjunctival swabs) were pooled and subsequently divided as follows: two aliquots of 200 μL were used for TNA extractions and 400 μL were used for virus isolation. TNA extraction was performed using 200 μL of sample or cell culture supernatant with the MagNa Pure LC (Roche Diagnostics AG, Rotkreuz, Switzerland) using the MagNa Pure LC Total Nucleic Acid Isolation Kit (Roche Diagnostics) following the manufacturer's instructions. In each batch of extraction, a negative control that consisted of 200 μl of PBS was used to monitor for cross-contamination. TNA was stored at -20°C until qPCR analysis.

**Virus isolation**

For virus isolation, 400 μl of each sample were filtered (Filtropur S 0.45 μm syringe filter, Sarstedt, Nümbrecht, Germany), incubated on 80% confluent Crandell-Rees feline kidney cells in 24-well plates (TPP Tissue Culture Testplate 24, TPP Techno Plastic Products AG, Trasadingen Switzerland) and cultured using RPMI 1640 Medium (Sigma-Aldrich Chemie GmbH, Steinheim Germany) supplemented with 10% heat inactivated fetal calf serum (Invitrogen, Basel, Switzerland), 2 mM L-Glutamin (Gibco, Life Technologies) and 1x Antibiotic-Antimycotic (Gibco, Life Technologies). For each sample culture, a negative medium-only control was run in parallel. The samples were incubated on cells for two hours before 300 μl of complete medium were added. The cells were fed daily and evaluated for the presence of a cytopathic effect. As soon as a cytopathic effect became visible or after a maximum of seven days, the supernatants were collected for TNA extraction and
for storage at -80°C until further use. If the TNA extraction could not be performed on
the day of collection, 300 µl Lysis Buffer (MagNa Pure LC Total Nucleic Acid Isolation
Kit, Roche Diagnostics) were added to the 200 µl of supernatant and the mixture was
stored at -20°C as recommended by the manufacturer. TNA was extracted from the
cell culture supernatants after a maximum of 72 hours of storage.

**Real-time qPCR and RT-qPCR assays**

All real-time qPCR assays in the current study were run with 5 µl TNA in an end
volume of 25 µl. Positive and negative controls were run with each RT-qPCR and
qPCR assay. All oligonucleotides were synthetized by Microsynth AG (Balgach,
Switzerland), and all qPCR assays were run on an ABI 7500Fast Real-Time PCR
system (Applied Biosystems, Rotkreuz, Switzerland). For quantitative analyses, CT-
values were used.

For FCV, two previously described FCV real-time TaqMan RT-qPCR assays were
used [25, 26]. The assays were optimized prior to the start of the experiment. The
FCV RT-qPCR S1 [25] reaction contained 1 x One step RT-qPCR MasterMix Low
ROX (Eurogentec), 300 nM forward primer, 900 nM reverse primer, 250 nM probe,
5 µl nuclease-free water (Gibco, Life Technologies) and 0.125 µl Euroscript
(Eurogentec). The temperature profile was 30 min at 48°C, followed by 10 min at
95°C and 45 cycles of 15 sec at 95°C, followed by 1 min at 60°C. The FCV RT-qPCR
S2 [26] reaction contained 0.5 µl Superscript III/RT Platinum Taq Mix (Invitrogen, Life
technologies), 300 nM forward primer, 900 nM reverse primer, 250 nM probe, 0.05 µl
2.5x Rox dye, 0.625 µl 40 U/µl rRNasin® RNase Inhibitor (Promega, Dübendorf,
Switzerland) or RNASin® Plus RNase Inhibitor (Promega) and 3.95 µl nuclease-free
water (Gibco, Life Technologies). The temperature profile was 30 min at 50°C,
followed by 2 min at 95°C and 45 cycles of 20 sec at 95°C, followed by 45 sec at
60°C. Each sample (TNA from swab/cytobrush and TNA from cell culture supernatant) was analyzed with both RT-qPCR assays (S1 and S2). All cats that tested positive in at least one of the four RT-qPCR runs were categorized as FCV-positive (FCV RT-qPCR S1 or qPCR S2 from swabs/cytobrush or from virus isolation).

TNA from swab/cytobrush from each cat was also tested for FHV-1 [43], C. felis [44], B. bronchiseptica [15] and M. felis [45] by qPCR using assays previously described methods. Moreover, the samples were also tested for FeLV [46] and FIV viral RNA [47] by RT-qPCR because both infections can lead to increased susceptibility to other infections and can be associated with inflammatory oral disease. Three samples from FCV-suspect cats could not be analyzed for B. bronchiseptica, M. felis, FeLV and FIV because of a lack of material.

**Statistical analysis**

Statistical analysis was performed utilizing the freely available software program R version 3.2.0 [48]. Separately for the FCV-suspect and clinically healthy cats, descriptive statistics with frequencies for male and female cats, medians with 95 % confidence interval (CI) for age and proportions of the dichotomous variables with 95 % CI based on the binomial distribution are presented. Regression models were applied to assess if the predictors (age in years, sex: male or female, reproductive status: intact or neutered, pedigree: yes or no, outdoor access, living in groups of at least four cats, being vaccinated at all or having received a primary immunization, having received immunosuppressive, antimicrobial and / or antiviral treatment or being co-infected with M. felis, FHV-1, C. felis and / or B. bronchiseptica) were significantly associated with the outcome FCV infection. Univariable regressions, with the outcome FCV were performed and odds ratios with 95 % Wald confidence
intervals are shown. Due to the presence of missing values which reduced the number of complete cases (meaning cats with information for all predictors) for FCV-suspect animals to 168 and for clinically healthy animals to 88, missing values were imputed with the package missForest [49], separately for the FCV-suspect and clinically healthy cats. Imputation was done iteratively based on a random forest approach. Utilizing the imputed data sets, multivariable logistic regressions were performed with the package MASS [50]. Models were built following two different approaches. First, all variables with a p-value < 2 in univariable regression were considered in different models, including interaction terms. Model selection was based on AIC (Akaike’s information criterion) with lower values of at least 2 considered indicative of a better model fit. In case of between model differences smaller than 2, the most parsimonious model was chosen. Second, a stepwise regression approach in both directions was applied including all variables, irrespective of their p-values in the univariate approach and interaction terms. Diagnostic plots were assessed for the robustness of the final models. Results are presented as odds ratios and 95 % Wald confidence intervals. FCV loads in swab/cytobrush samples were compared between two groups using the Mann-Whitney U-test (pMWU) and the Graph-Pad Prism Version 3.0 (GraphPad Software, San Diego, CA, USA). Maps were produced using QGIS Geographic Information System (v. 2.6.1) [51]. Canton boundaries were provided by the Swiss Federal Office of Topography.

**Results**

Summary statistics for all variables used in the statistical analysis for FCV-suspect and healthy cats are presented in Table 1. This includes the PCR results for URTD-associated pathogens. FCV infection was detected in 45% (95% CI 38 - 52%) of the FCV-suspect cats and in 8% (95% CI 4 - 15%) of the healthy cats. Among the 200
FCV-suspect and 100 healthy cats, 40% (95% CI 33 – 47%) and 14% (95% CI 8 – 22%) respectively, were co-infected with any of the tested URTD-associated pathogens. In summary, among the co-infected FCV-suspect cats, 77% were positive for two, 21% for three and 3% for four pathogens. Among the co-infected healthy cats, 93% were positive for two and 7% for three pathogens. For details see Additional file 1. In 26% (95% CI 20 - 33%) of the FCV-suspect cats, none of the tested URTD-associated pathogens were detected. Five cats (four FCV-suspect and one healthy cat, 2.5%, 95% CI 0.8 - 6%) tested positive either for FeLV or for FIV. Because of the low prevalence, FIV and FeLV infections were not considered in the statistical analysis. Approximately two thirds of the cats lived in a group with other cats (Table 1); details of the numbers of cats per group and the frequency of FCV infection are shown in Additional file 2. The majority of the FCV-suspect (76%, 95% CI 69 - 82%) and healthy cats (80%, 95% CI 70 - 87%) were vaccinated; of these 92% of the FCV-suspect and healthy cats had received a primary immunization defined as a minimum of two vaccinations two to six weeks apart with the same vaccine strain (Table 1). In both groups of cats, the vaccine strain most frequently used for primary immunization was FCV F9 (FCV-suspect cats: 90%, 95% CI 82 - 95%; healthy cats: 86%, 95% CI 75 - 93%) followed by FCV G1/431 (FCV-suspect cats: 18%, 95% CI 11 - 28%; healthy cats: 11%, 95% CI 5 - 22%). Because of the small number of cats vaccinated with a vaccine strain other than F9, vaccine strain was not considered in the statistical analysis.

Based on univariable regression models, in FCV-suspect cats intact reproductive status, living in a group of at least four cats, co-infection with *M. felis* and both vaccination and primary immunization were found to be significantly associated with FCV infection (Table 2). The former three predictors were found to be risk factors by approximately doubling the chance of a FCV infection (if being intact versus
neutered, if living in a group of at least four cats and if being co-infected with *M. felis*).

Being vaccinated at all or having received a primary immunization were found to be protective factors by reducing the chance of a FCV infection by approximately 50 %.

In contrast, amongst the clinically healthy cats, the vaccination predictors were not significantly associated with FCV infection (Table 2). Similarly to the FCV-suspect cats, intact reproductive status and living in a group of at least four cats were found to be risk factors, albeit with higher odds ratios and considerably larger confidence intervals than in the FCV-suspect cats. Details on missing values, univariable regressions with complete case and imputed data sets are presented in Additional file 3. Whereas p-values obtained with the original data and the imputed data are similar, p-values from complete case analyses differ slightly.

Based on multivariable regression models, in FCV-suspect animals only intact reproductive status, living in a group of at least four cats and co-infection with *M. felis* remained in the final model with all odds ratios being reduced by at least 10 % compared to the univariable results (Table 3). Based on the stepwise regression with all predictors, outdoor access was additionally found to be a risk factor for FCV infection (data not shown). None of the variables describing vaccination were found to be significant in the multivariable models. Regarding the clinically healthy cats, intact reproductive status and living in a group of at least four cats remained in the final model with higher odds ratios and larger confidence intervals than in the FCV-suspect cats. Stepwise regression was not possible for this group of cats due to lack of convergence.

The clinical signs in the 200 cats chosen by the veterinary practitioners because of FCV-related symptoms are shown in Table 4. In approximately half of the FCV-suspect cats, gingivitis or classical signs of URTD, such as nasal discharge, ocular discharge, conjunctivitis and sneezing were present. Approximately one third of the
cats exhibited stomatitis or caudal stomatitis, about 10% demonstrated oral or lingual ulceration and only a few were found with swollen joints, lameness, cutaneous ulcerations or cutaneous edema. Gingivitis, stomatitis, caudal stomatitis, salivation and oral and lingual ulcerations were significantly associated with FCV infection (Table 4). In contrast, nasal and ocular discharge and sneezing were significantly less common in the FCV PCR-positive than in the FCV PCR-negative cats. When the FCV load in the sample material was compared between FCV-positive diseased and FCV-positive healthy cats, the FCV loads were higher in the diseased cats, although statistical significance was not reached (FCV S1 RT-qPCR; \( p_{\text{MWU}} = 0.07 \); Figure 2).

**Discussion**

The present study investigated FCV infection in 200 diseased cats judged suspicious for FCV infection by private veterinarians and in 100 clinically healthy cats, all sampled in different regions of Switzerland. FCV infection was detected in 45% (95% CI 38 – 52%) of the cats with FCV-related symptoms. This relatively low percentage of PCR-positive symptomatic cats is in agreement with the prevalence of FCV infection in cats in UK with respiratory disease (33%, 95% CI 27 - 39%) [19] and in cats in Germany with chronic gingivostomatitis (54%, 95% CI 39 - 68%) [5]. In the present study, cats were judged as FCV-suspect by the veterinary practitioners based on written instructions that listed FCV-related symptoms as described in the literature [2, 40]. Interestingly, cats suffering from gingivitis and URTD-related symptoms were most commonly selected by the veterinarians. However, only gingivitis, stomatitis, salivation and oral and lingual ulcerations were significantly associated with FCV infection but not the classical signs of URTD, such as sneezing, nasal and ocular discharge. In contrast, sneezing, nasal and ocular discharge were significantly less common in the FCV-positive cats when compared to the FCV-negative cats. This finding contrasts earlier studies where FCV infection was
significantly associated with feline respiratory tract disease [14, 15, 19, 52]. However, in accordance with our results, Bannasch and co-workers found that among the five pathogens associated with URTD examined (the same as in the present study), the most important contributors to URTD were FHV-1, *Mycoplasma* species and *C. felis* [16]. Acute FCV is known to induce vesicular disease, which typically manifests as oral and lingual ulcerations [53]. Ocular and nasal discharge is only rarely reported after experimental FCV infection [6, 36, 54]. Chronic FCV infection has been strongly associated with the presence of gingivostomatitis [5], although the exact pathogenesis of this disease is still unknown. Our data suggest that for a clinical diagnosis of FCV infection, the FCV-related symptoms should be reconsidered and more stringently defined and the diagnosis confirmed by molecular testing.

It needs to be noted that the relatively low detection rate of FCV in the FCV-suspect cats could also be attributed to a limited diagnostic sensitivity of the applied diagnostic assays. In the current study, the criterion of being FCV-positive was based on the presence of at least one positive out of four real-time RT-qPCR runs (two different PCR assays performed directly from the sample material and after an enrichment step in cell culture). This approach was chosen to maximize diagnostic sensitivity. However, the remarkably high genetic variability of FCV [55, 56] increases the likelihood of potential mismatches in the primer or probe binding sites, thus leading to the possibility of failed real-time PCR amplification.

Interestingly, 26% of the FCV-suspect cats tested negative for all URTD-associated pathogens. Cats with a non-infectious etiology for URTD (i.e., neoplasia, foreign bodies or immune-mediated rhinitis) could account for some of these cases. Cats with non-infectious URTD are clinically indistinguishable from cats with URTD caused by infectious agents. Additionally, the detection of the URTD-associated pathogens could have failed due to sample degradation during the transport from the veterinary
practices to the laboratory [2]. To avoid or minimize this effect, the samples in the present study were analyzed within 96 hours of collection. Finally, the diagnostic sensitivity of the PCR assays could have been hampered by genetic alterations of the pathogens within the target sequence of the applied PCR assays. However, in contrast to RNA viruses such as FCV, a high genetic variability is not necessarily expected for FHV-1, *C. felis*, *M. felis* and *B. bronchiseptica*.

Approximately 8 - 9% of the healthy cats in the present study tested PCR-positive for FHV-1 and FCV. This proportion is lower than reported in earlier studies in the UK (22%, 95% CI 17 - 29%) [19] and in Germany (14%, 95% CI 6 – 27%) [5]. As previously reported [52], it is important to remember that some cats, although clinically healthy, are shedders of infectious pathogens related to URTD.

In the present study, risk factor analysis was performed with univariable and multivariable regression models. The latter were performed with imputed data sets due to missing data. The selected multivariable regression approach offers, in contrast to univariable approaches, the possibility to adjust for confounding. Inevitably however, it remains possible that not all relevant confounders were recorded. Missing values leading subsequently to different sample sizes of models with different variables, preclude the possibility to compare the model fit: thus data sets with imputed variables for the missing values were generated. Although resulting p-values obtained with the original and the imputed data sets were similar in univariable analysis, any imputation may potentially include bias. Two model-building approaches were performed for the FCV-suspect cats (the stepwise approach was not possible for the clinically healthy cats) to assure robustness of the final models.

Although found to be significant protective factors in univariable models, statistical association for vaccination status and primary immunization vanished in multivariable
analysis. One reason might be that the predictors “vaccination status” and “primary immunization” with the categories “yes” and “no” (or “unknown” in 18 and 8 cases for the FCV-suspect and healthy cats respectively) comprised a number of different vaccines, vaccinations schemes and time elapsed since vaccination, thus, potentially being too heterogeneous to actually show a statistical association. In addition, FCV vaccines do not induce sterilizing immunity, although they have been shown to reduce the severity of clinical signs [30, 31]. Therefore, vaccine protection cannot be solely judged by the PCR status of a cat. Furthermore, a cross-sectional study is rather limited in assessing causal relationships, especially since in a cross-sectional approach only prevalence can be estimated whereas incidence would be more relevant.

An intact reproductive status, living in a group with at least four cats and co-infection with *M. felis* were found to be risk factors for FCV infection. All of these three factors approximately doubled the chance of finding a FCV infection. A number of interaction terms, including interaction between groups of at least four cats and *M. felis* or between vaccination and intact reproductive status, were tested for potential association but none was found to be statistically significant.

An association of FCV with intact reproductive status has been reported in an earlier study [52]. Although no clear explanation can be given for this association, possible reasons postulated earlier include hormonal effects, which might alter the replication and the persistence of the virus, and more social or aggressive interactions between the intact animals [52].

The association of FCV infection with housing in large groups of cats was reported in previous studies [34, 57]. Cats held in large groups are exposed to a higher infectious pressure compared with cats living in smaller groups. The high plasticity of
the FCV genome and positive selection by the immune system support genomic mutations and lead to a progressive evolution of FCV variants in cat groups with cyclic reinfection of previously immune cats [58, 59]. In addition, strict quarantine measures and excellent hygiene can be more challenging to guarantee in large groups of cats, thereby favoring FCV infections [15]. Breeders and other cat owners should be educated about the benefits of housing cats in small groups. A reduced group size does not only reduce the risk of infection related to URTD in cats but also the risk of other feline infections and the development of feline infectious peritonitis [60, 61].

No clear explanation can be given for the association of FCV infection with *M. felis* co-infection. Possible reasons could be a similar transmission route, pathogenesis or similar risk factors for infection. FCV and FHV-1 infection have often been reported to occur concurrently, and cats co-infected with FCV and FHV-1 had a high risk of developing URTD [62]. However, no association between FCV infection and co-infections with the other tested pathogens FHV-1, *C. felis* and *B. bronchiseptica* were found in the present study.

The different housing categories including private home, farm, breeder, feral cat and cattery were recorded in this study, but since the vast majority of cats was kept in private homes, it was not possible to disentangle the effect of different housing categories. The variable breed was dichotomized into pedigree and non-pedigree cats for statistical analysis because the number of cats per breed was small. The absence of a statistical association does therefore not preclude any potential association between specific breeds and FCV infection. For example out of 17 FCV-suspect Maine Coons, 13 were found to be FCV-infected and suffer from gingivostomatitis. It is known that purebreds, such as the Maine Coons, are predisposed to develop early or severe periodontal disease [63], but no association
with FCV infection has been described thus far. It should be noted however that 12 of 
the FCV-positive Main Coons were housed in groups (data not shown).

In the present study, 76% and 80% of the FCV-suspect and healthy cats, 
respectively, were vaccinated against FCV and FHV-1 (i.e. had received some 
vaccinations against FCV and FHV-1 at any time point). This vaccination rate seems 
higher than the rate estimated for Switzerland in 2009 according to the number of 
sold vaccine doses (30 to 40% of all Swiss cats vaccinated) [64]. Thus, according to 
our numbers, the proportion of vaccinated cats would be sufficiently high to provide 
some protection for the population (herd immunity) within the sampled population as 
opposed to protection of the vaccinated host only [65]. However, the present study is 
based on preselected populations of cats and some of the cats had not received a 
proper primary immunization or were lacking the necessary booster vaccinations, 
leaving some doubts about the actual level of protection.

**Conclusion**

The present study assessed FCV infection in cats judged FCV-suspect by veterinary 
practitioners and in clinically healthy cats in Switzerland. FCV infection was detected 
in less than half of the FCV-suspect cats. Within this group of cats, infection was 
significantly associated with gingivitis, stomatitis, oral and lingual ulcerations, but not 
with classical signs of URTD, such as sneezing, nasal and ocular discharge. These 
results suggest that the FCV-related symptoms should be critically reassessed and 
probably more stringently defined. FCV infection was also detected in some healthy 
cats; this observation underlines the importance of asymptomatic shedders in FCV 
epidemiology. Housing in large groups of cats was among the risk factors for FCV 
infection. Thus, if problems with FCV infection are encountered in multi-cat
environments, reduction of group size in addition to the generally recommended vaccination and quarantine measures for incoming and sick cats are advocated.

List of abbreviations

B. bronchiseptica = Bordetella bronchiseptica; C. felis = Chlamydophila felis; FCV = Feline calicivirus; FHV-1 = Feline herpesvirus-1; M. felis = Mycoplasma felis; qPCR = quantitative polymerase chain reaction; RT-qPCR = reverse-transcriptase qPCR; CI = confidence interval; URTD = upper respiratory tract disease; FeLV = Feline leukemia virus; FIV = Feline immunodeficiency virus; TNA = Total nucleic acid.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

HL and RHL conceived the study. BW, FSB and RHL participated in the design and coordination of the study. AB carried out the sample and data collection and part of the laboratory work. BW and FSB were responsible for clinical aspects of the study. MLM was responsible for all laboratory aspects. RHL, SH, AD and AB performed the statistical analysis. BW, RHL and AB drafted the manuscript. MM, FSB, SH and HL edited the manuscript. All authors read and approved the final manuscript.

Acknowledgements

The composition of the in-house produced viral transport medium was kindly provided by the Diagnostic Department of the Institute of Medical Virology, University of Zürich, Switzerland. The authors thank all participating veterinarians for collecting the samples and case information, B. Weibel, T. Meili Prodan, E. Goenczi and C. Asquith for excellent laboratory assistance and F. Mavrot for providing the maps of
the Swiss cantons. The laboratory work was performed using the logistics of the Center for Clinical Studies, Vetsuisse Faculty, University of Zurich. The study was partially funded by a research grant from Merial, Lyon, France, and Biokema SA, Crissier-Lausanne, Switzerland. This study was the doctoral thesis of A. Berger.

References

1. Harrison TM, Sikarskie J, Kruger J, Wise A, Mullaney TP, Kiupel M et al. Systemic calicivirus epidemic in captive exotic felids. J Zoo Wildl Med. 2007;38(2):292-9.

2. Radford AD, Addie D, Belak S, Boucraut-Baralon C, Egberink H, Frymus T et al. Feline calicivirus infection. ABCD guidelines on prevention and management. J Feline Med Surg. 2009;11(7):556-64. doi:S1098-612X(09)00116-8 [pii] 10.1016/j.jfms.2009.05.004.

3. Reubel GH, Hoffmann DE, Pedersen NC. Acute and chronic faucitis of domestic cats. A feline calicivirus-induced disease. Vet Clin North Am Small Anim Pract. 1992;22(6):1347-60.

4. Wardley RC, Povey RC. The pathology and sites of persistence associated with three different strains of feline calicivirus. Res Vet Sci. 1977;23(1):15-9.

5. Belgard S, Truyen U, Thibault JC, Sauter-Louis C, Hartmann K. Relevance of feline calicivirus, feline immunodeficiency virus, feline leukemia virus, feline herpesvirus and Bartonella henselae in cats with chronic gingivostomatitis. Berl Munch Tierarztl Wochenschr. 2010;123(9-10):369-76.

6. TerWee J, Lauritzen AY, Sabara M, Dreier KJ, Kokjohn K. Comparison of the primary signs induced by experimental exposure to either a pneumotrophic or a 'limping' strain of feline calicivirus. Vet Microbiol. 1997;56(1-2):33-45. doi:S0378-1135(96)01344-2 [pii]
7. Dawson S, Bennett D, Carter SD, Bennett M, Meanger J, Turner PC et al. Acute arthritis of cats associated with feline calicivirus infection. Res Vet Sci. 1994;56(2):133-43. doi:0034-5288(94)90095-7 [pii].

8. Levy JK, Marsh A. Isolation of calicivirus from the joint of a kitten with arthritis. Journal of the American Veterinary Medical Association. 1992;201(5):753-5.

9. Pedersen NC, Elliott JB, Glasgow A, Poland A, Keel K. An isolated epizootic of hemorrhagic-like fever in cats caused by a novel and highly virulent strain of feline calicivirus. Vet Microbiol. 2000;73(4):281-300. doi:S0378-1135(00)00183-8 [pii].

10. Schorr-Evans EM, Poland A, Johnson WE, Pedersen NC. An epizootic of highly virulent feline calicivirus disease in a hospital setting in New England. J Feline Med Surg. 2003;5(4):217-26. doi:S1098612X03000081 [pii].

11. Coyne KP, Jones BR, Kipar A, Chantrey J, Porter CJ, Barber PJ et al. Lethal outbreak of disease associated with feline calicivirus infection in cats. Vet Rec. 2006;158(16):544-50. doi:158/16/544 [pii].

12. Reynolds BS, Poulet H, Pingret JL, Jas D, Brunet S, Lemeter C et al. A nosocomial outbreak of feline calicivirus associated virulent systemic disease in France. J Feline Med Surg. 2009;11(8):633-44. doi:S1098-612X(08)00278-7 [pii] 10.1016/j.jfms.2008.12.005.

13. Schulz BS, Hartmann K, Unterer S, Eichhorn W, Majzoub M, Homeier-Bachmann T et al. Two outbreaks of virulent systemic feline calicivirus infection in cats in Germany. Berl Munch Tierarztl Wochenschr. 2011;124(5-6):186-93.
14. Cai Y, Fukushi H, Koyasu S, Kuroda E, Yamaguchi T, Hirai K. An etiological investigation of domestic cats with conjunctivitis and upper respiratory tract disease in Japan. J Vet Med Sci. 2002;64(3):215-9.

15. Helps CR, Lait P, Damhuis A, Bjornehammar U, Bolta D, Brovida C et al. Factors associated with upper respiratory tract disease caused by feline herpesvirus, feline calicivirus, *Chlamydophila felis* and *Bordetella bronchiseptica* in cats: experience from 218 European catteries. Vet Rec. 2005;156(21):669-73. doi:156/21/669 [pii].

16. Bannasch MJ, Foley JE. Epidemiologic evaluation of multiple respiratory pathogens in cats in animal shelters. J Feline Med Surg. 2005;7(2):109-19. doi:S1098-612X(04)00126-3 [pii] 10.1016/j.jfms.2004.07.004.

17. Hoover EA, Kahn DE. Experimentally induced feline calicivirus infection: clinical signs and lesions. Journal of the American Veterinary Medical Association. 1975;166(5):463-8.

18. Harbour DA, Howard PE, Gaskell RM. Isolation of feline calicivirus and feline herpesvirus from domestic cats 1980 to 1989. Vet Rec. 1991;128(4):77-80.

19. Binns SH, Dawson S, Speakman AJ, Cuevas LE, Hart CA, Gaskell CJ et al. A study of feline upper respiratory tract disease with reference to prevalence and risk factors for infection with feline calicivirus and feline herpesvirus. J Feline Med Surg. 2000;2(3):123-33. doi:10.1053/jfms.2000.0084 S1098612X00900846 [pii].

20. Foster SF, Barrs VR, Martin P, Malik R. Pneumonia associated with *Mycoplasma* spp in three cats. Aust Vet J. 1998;76(7):460-4.
21. Foley JE, Rand C, Bannasch MJ, Norris CR, Milan J. Molecular epidemiology of feline bordetellosis in two animal shelters in California, USA. Prev Vet Med. 2002;54(2):141-56. doi:S0167587702000223 [pii].

22. Hartmann A, Hartmann K. [Treatment and management of *Chlamydophila felis* infections in cats]. Tierarztl Prax Ausg K Kleintiere Heimtiere. 2010;38(4):217-26. doi:10040217 [pii].

23. Masubuchi K, Nosaka H, Iwamoto K, Kokubu T, Yamanaka M, Shimizu Y. Experimental infection of cats with *Chlamydophila felis*. J Vet Med Sci. 2002;64(12):1165-8.

24. McArdle HC, Dawson S, Coutts AJ, Bennett M, Hart CA, Ryvar R et al. Seroprevalence and isolation rate of *Bordetella bronchiseptica* in cats in the UK. Vet Rec. 1994;135(21):506-7.

25. Helps C, Lait P, Tasker S, Harbour D. Melting curve analysis of feline calicivirus isolates detected by real-time reverse transcription PCR. J Virol Methods. 2002;106(2):241-4. doi:S0166093402001672 [pii].

26. Abd-Eldaim MM, Wilkes RP, Thomas KV, Kennedy MA. Development and validation of a TaqMan real-time reverse transcription-PCR for rapid detection of feline calicivirus. Arch Virol. 2009;154(4):555-60. doi:10.1007/s00705-009-0337-5.

27. Sykes JE, Studdert VP, Browning GF. Detection and strain differentiation of feline calicivirus in conjunctival swabs by RT-PCR of the hypervariable region of the capsid protein gene. Arch Virol. 1998;143(7):1321-34.

28. Marsilio F, Di Martino B, Decaro N, Buonavoglia C. A novel nested PCR for the diagnosis of calicivirus infections in the cat. Vet Microbiol. 2005;105(1):1-7. doi:10.1016/j.vetmic.2004.09.017.
29. Wilhelm S, Truyen U. Real-time reverse transcription polymerase chain reaction assay to detect a broad range of feline calicivirus isolates. J Virol Methods. 2006;133(1):105-8. doi:10.1016/j.jviromet.2005.10.011.

30. Orr CM, Gaskell CJ, Gaskell RM. Interaction of a combined feline viral rhinotracheitis-feline calicivirus vaccine and the FVR carrier state. Vet Rec. 1978;103(10):200-2.

31. Bittle JL, Rubic WJ. Immunization against feline calicivirus infection. Am J Vet Res. 1976;37(3):275-8.

32. Radford AD, Dawson S, Coyne KP, Porter CJ, Gaskell RM. The challenge for the next generation of feline calicivirus vaccines. Vet Microbiol. 2006;117(1):14-8. doi:S0378-1135(06)00138-6 [pii] 10.1016/j.vetmic.2006.04.004.

33. Lauritzen A, Jarrett O, Sabara M. Serological analysis of feline calicivirus isolates from the United States and United Kingdom. Vet Microbiol. 1997;56(1-2):55-63. doi:S0378-1135(96)01252-7 [pii] 10.1016/S0378-1135(96)01252-7.

34. Porter CJ, Radford AD, Gaskell RM, Ryvar R, Coyne KP, Pinchbeck GL et al. Comparison of the ability of feline calicivirus (FCV) vaccines to neutralise a panel of current UK FCV isolates. J Feline Med Surg. 2008;10(1):32-40. doi:S1098-612X(07)00133-7 [pii] 10.1016/j.jfms.2007.06.011.

35. Addie D, Poulet H, Golder MC, McDonald M, Brunet S, Thibault JC et al. Ability of antibodies to two new caliciviral vaccine strains to neutralise feline calicivirus isolates from the UK. Vet Rec. 2008;163(12):355-7. doi:163/12/355 [pii].
36. Poulet H, Brunet S, Leroy V, Chappuis G. Immunisation with a combination of two complementary feline calicivirus strains induces a broad cross-protection against heterologous challenges. Vet Microbiol. 2005;106(1-2):17-31. doi:S0378-1135(04)00467-5 [pii]
10.1016/j.vetmic.2004.12.010.

37. Huang C, Hess J, Gill M, Hustead D. A dual-strain feline calicivirus vaccine stimulates broader cross-neutralization antibodies than a single-strain vaccine and lessens clinical signs in vaccinated cats when challenged with a homologous feline calicivirus strain associated with virulent systemic disease. J Feline Med Surg. 2010;12(2):129-37. doi:S1098-612X(09)00228-9 [pii]
10.1016/j.jfms.2009.08.006.

38. Masubuchi K, Wakatsuki A, Iwamoto K, Takahashi T, Kokubu T, Shimizu M. Immunological and genetic characterization of feline caliciviruses used in the development of a new trivalent inactivated vaccine in Japan. Journal of Veterinary Medical Science. 2010;72(9):1189-94.

39. Schweizerische Eidgenossenschaft: Schweizer Tierschutzgesetz (TSchG). 2008. https://www.admin.ch/opc/de/classified-compilation/20022103/index.html. Accessed 18 August 2015.

40. Gerriets W, Joy N, Huebner-Guthardt J, Eule JC. Feline calicivirus: a neglected cause of feline ocular surface infections? Vet Ophthalmol. 2012;15(3):172 - 9. doi:doi:10.1111/j.1463-5224.2011.00957.x.

41. Willi B, Boretti FS, Baumgartner C, Tasker S, Wenger B, Cattori V et al. Prevalence, risk factor analysis, and follow-up of infections caused by three feline
hemoplasma species in cats in Switzerland. Journal of clinical microbiology. 2006;44(3):961-9. doi:10.1128/JCM.44.3.961-969.2006.

42. Lutz H, Lehmann R, Winkler G, Kottwitz B, Dittmer A, Wolfensberger C et al. [Feline immunodeficiency virus in Switzerland: clinical aspects and epidemiology in comparison with feline leukemia virus and coronaviruses]. Schweizer Archiv fur Tierheilkunde. 1990;132(5):217-25.

43. Vogtlin A, Fraefel C, Albini S, Leutenegger CM, Schraner E, Spiess B et al. Quantification of feline herpesvirus 1 DNA in ocular fluid samples of clinically diseased cats by real-time TaqMan PCR. Journal of clinical microbiology. 2002;40(2):519-23.

44. Helps C, Reeves N, Egan K, Howard P, Harbour D. Detection of Chlamyphila felis and feline herpesvirus by multiplex real-time PCR analysis. Journal of clinical microbiology. 2003;41(6):2734-6.

45. Soderlund R, Bolske G, Holst BS, Aspan A. Development and evaluation of a real-time polymerase chain reaction method for the detection of Mycoplasma felis. J Vet Diagn Invest. 2011;23(5):890-3. doi:1040638711407479 [pii] 10.1177/1040638711407479.

46. Tandon R, Cattori V, Gomes-Keller MA, Meli ML, Golder MC, Lutz H et al. Quantitation of feline leukaemia virus viral and proviral loads by TaqMan real-time polymerase chain reaction. J Virol Methods. 2005;130(1-2):124-32. doi:S0166-0934(05)00212-0 [pii] 10.1016/j.jviromet.2005.06.017.

47. Klein D, Leutenegger CM, Bahula C, Gold P, Hofmann-Lehmann R, Salmons B et al. Influence of preassay and sequence variations on viral load determination by a
multiplex real-time reverse transcriptase-polymerase chain reaction for feline immunodeficiency virus. Journal of acquired immune deficiency syndromes. 2001;26(1):8-20.

48. R-Core-Team. A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2015. http://www.R-project.org. Accessed 11 July 2015 2015.

49. Stekhoven D, Buehlmann P. MissForest - non-parametric missing value imputation for mixed-type data. Bioinformatics. 2012;28:112-8.

50. Venables W, Ripley B. Modern Applied Statistics with S. 4th ed. New York: Springer; 2002.

51. QGIS Development Team. QGIS Geographic Information System. Open Source Geospatial Foundation Project. Brighton. 2014. http://qgis.osgeo.org. Accessed 18 August 2015.

52. Wardley RC, Gaskell RM, Povey RC. Feline respiratory viruses--their prevalence in clinically healthy cats. J Small Anim Pract. 1974;15(9):579-86.

53. Pesavento PA, Chang KO, Parker JS. Molecular virology of feline calicivirus. Vet Clin North Am Small Anim Pract. 2008;38(4):775-86, vii. doi:10.1016/j.cvsm.2008.03.002.

54. Lesbros C, Martin V, Najbar W, Sanquer A, McGahie D, Eun HM et al. Protective efficacy of the calicivirus valency of the leucofeligen vaccine against a virulent heterologous challenge in kittens. Vet Med Int. 2013;2013:232397. doi:10.1155/2013/232397.
55. Coyne KP, Christley RM, Pybus OG, Dawson S, Gaskell RM, Radford AD. Large-scale spatial and temporal genetic diversity of feline calicivirus. J Virol. 2012;86(20):11356-67. doi:JVI.00701-12 [pii]
10.1128/JVI.00701-12.

56. Radford AD, Dawson S, Ryvar R, Coyne K, Johnson DR, Cox MB et al. High genetic diversity of the immunodominant region of the feline calicivirus capsid gene in endemically infected cat colonies. Virus Genes. 2003;27(2):145-55. doi:5142895 [pii].

57. Zicola A, Saegerman C, Quatpers D, Viandier J, Thiry E. Feline herpesvirus 1 and feline calicivirus infections in a heterogeneous cat population of a rescue shelter. J Feline Med Surg. 2009;11(12):1023-7. doi:S1098-612X(09)00165-X [pii]
10.1016/j.jfms.2009.05.023.

58. Radford AD, Turner PC, Bennett M, McArdle F, Dawson S, Glenn MA et al. Quasispecies evolution of a hypervariable region of the feline calicivirus capsid gene in cell culture and in persistently infected cats. J Gen Virol. 1998;79 (Pt 1):1-10.

59. Coyne KP, Edwards D, Radford AD, Cripps P, Jones D, Wood JL et al. Longitudinal molecular epidemiological analysis of feline calicivirus infection in an animal shelter: a model for investigating calicivirus transmission within high-density, high-turnover populations. Journal of clinical microbiology. 2007;45(10):3239-44. doi:JCM.01226-07 [pii]
10.1128/JCM.01226-07.

60. Addie D, Belak S, Boucraut-Baralon C, Egberink H, Frymus T, Gruffydd-Jones T et al. Feline infectious peritonitis. ABCD guidelines on prevention and management. J Feline Med Surg. 2009;11(7):594-604. doi:10.1016/j.jfms.2009.05.008.
61. Foley JE, Poland A, Carlson J, Pedersen NC. Risk factors for feline infectious peritonitis among cats in multiple-cat environments with endemic feline enteric coronavirus. Journal of the American Veterinary Medical Association. 1997;210(9):1313-8.

62. Gaskell CJ, Radford A, Dawson S. Feline infectious respiratory disease. In: Chandler EA, Gaskell CJ, Gaskell RM, editors. Feline Medicine and Therapeutics. 3rd Edition ed. Oxford: Blackwell Publishing; 2004. p. 577–95.

63. Girard N, Servet E, Biourge V, Hennet P. Periodontal health status in a colony of 109 cats. J Vet Dent. 2009;26(3):147-55.

64. Gesellschaft Schweizerischer Tierärztinnen und Tierärte GST, Schweizerische Vereinigung für Kleintiermedizin (SVK). Geliebt! Geimpft? Gesunde Tiere machen Freude. www.geliebtgeimpft.ch. Accessed 5 February 2015.

65. Horzinek MC, Thiry E. Vaccines and vaccination: the principles and the polemics. J Feline Med Surg. 2009;11(7):530-7. doi:S1098-612X(09)00113-2 [pii] 10.1016/j.jfms.2009.05.012.
Tables

**Table 1: Characteristics of the 200 FCV-suspect and the 100 healthy cats.** The cats originated from 19 different cantons in Switzerland.

| Parameter                              | FCV-suspect cats (n = 200) | Healthy cats (n = 100) |
|----------------------------------------|-----------------------------|------------------------|
|                                        | Median | Lower 95% CI | Upper 95% CI | Median | Lower 95% CI | Upper 95% CI |
| Age (years)                            |        | 0.20        | 16          | 0.75   | 0.3           | 14.8         |
| **Proportion**                         |        |             |             |        |              |              |
| Sex (male)                             | 0.60   | 0.52        | 0.66        | 0.61   | 0.51          | 0.71         |
| Intact reproductive status             | 0.37   | 0.30        | 0.44        | 0.40   | 0.30          | 0.50         |
| Pedigree                               | 0.32   | 0.25        | 0.39        | 0.22   | 0.14          | 0.32         |
| Breed[^]                               |        |             |             |        |              |              |
| Maine Coon                            | 0.09   | 0.05        | 0.14        | 0.02   | 0.01          | 0.07         |
| British Shorthair                     | 0.05   | 0.02        | 0.09        | 0.02   | 0.01          | 0.07         |
| Norwegian Forest Cat                  | 0.05   | 0.02        | 0.09        | 0.02   | 0.01          | 0.07         |
| Persian                               | 0.04   | 0.02        | 0.08        | 0.04   | 0.01          | 0.1          |
| Siamese                               | 0.03   | 0.01        | 0.06        | 0.02   | 0.01          | 0.07         |
| Multi-cat household                   | 0.72   | 0.65        | 0.78        | 0.63   | 0.53          | 0.72         |
| Group housing with ≥ 4 cats           | 0.22   | 0.16        | 0.29        | 0.16   | 0.09          | 0.25         |
| Outdoor access                        | 0.57   | 0.50        | 0.64        | 0.58   | 0.48          | 0.68         |
| Contact with dog with kennel cough    | 0.02   | 0        | 0.05        | 0.01   | 0             | 0.06         |
| Vaccinated                            | 0.76   | 0.69        | 0.82        | 0.80   | 0.70          | 0.87         |
| Primary immunization[^†]              | 0.69   | 0.61        | 0.75        | 0.72   | 0.61          | 0.81         |
| Immunosuppressive therapy             | 0.15   | 0.10        | 0.20        | 0.01   | 0.00          | 0.05         |
| Antibiotic therapy                    | 0.42   | 0.35        | 0.49        | 0.02   | 0.00          | 0.07         |
| Antiviral therapy                     | 0.05   | 0.02        | 0.08        | 0.00   | 0.00          | 0.04         |
| FCV positive*                         | 0.45   | 0.38        | 0.52        | 0.08   | 0.04          | 0.15         |
| *M. felis* positive*                  | 0.48   | 0.41        | 0.55        | 0.31   | 0.22          | 0.41         |
| *FHV-1 positive*                      | 0.20   | 0.15        | 0.26        | 0.09   | 0.04          | 0.16         |
| *C. felis* positive*                  | 0.08   | 0.05        | 0.13        | 0.01   | 0.00          | 0.05         |
| *B. bronchiseptica* positive*         | 0.04   | 0.02        | 0.08        | 0.02   | 0.00          | 0.07         |

[^] CI =Confidence interval.[^] Only breeds with >5 cats in the study are listed. *Due to low numbers, these variables were not considered in the statistical analysis.[^†] Primary immunization defined as two subsequent vaccinations within 2 to 6 weeks with the same vaccine strain. * Positive by real-time qPCR / RT-qPCR.
Table 2: Results of the univariable approach for the 200 FCV-suspect and the 100 healthy cats. Parameters significantly associated with FCV infection are shown in bold. Odds ratios and confidence intervals are given for p< 0.1.

| Parameter                          | FCV-suspect cats (n = 200) | Healthy cats (n = 100) |
|------------------------------------|-----------------------------|------------------------|
|                                    | p-value | Odds ratio | Lower 95% CI | Upper 95% CI | Odds ratio | Lower 95% CI | Upper 95% CI |
| Age                                | 0.12    | 0.70       |              |              | 0.70       |              |              |
| Sex                                | 0.38    | 0.51       |              |              |            |              |              |
| Intact reproductive status         | 0.02    | 2.02       | 1.13         | 3.62         | 0.02       | 12.52       | 1.48         | 106.20       |
| Pedigree                           | 0.87    |            |              |              | 0.28       |              |              |
| Multi-cat household                | 0.09    | 1.76       | 0.92         | 3.37         | 0.17       |              |              |
| Group housing with ≥ 4 cats        | **0.008** | **2.63** | **1.29**     | **5.37**     | <0.001     | **26.33**   | **4.61**     | **150.42**   |
| Outdoor access                     | 0.19    |            |              |              | 0.23       |              |              |
| Vaccinated                         | **0.03** | **0.48**   | **0.24**     | **0.94**     | 0.57       |              |              |
| Primary Immunization ‡             | **0.03** | **0.49**   | **0.26**     | **0.92**     | 0.83       |              |              |
| Immunosuppressive therapy          | 0.40    |            |              |              | 1.00       |              |              |
| Antibiotic therapy                 | 0.26    |            |              |              | 0.99       |              |              |
| Antivirale therapy                 | 0.51    |            |              |              | NA †       |              |              |
| M. felis positive*                 | **0.02** | **2.03**   | **1.15**     | **3.59**     | 0.06       | 4.23        | 0.94         | 18.99        |
| FHV-1 positive*                    | 0.78    |            |              |              | 0.99       |              |              |
| C. felis positive*                 | 0.27    |            |              |              | 0.99       |              |              |
| B. bronchiseptica positive*        | 0.74    |            |              |              | 0.99       |              |              |

*CI = Confidence interval of OR (given if p-values < 0.1). †Primary immunization defined as two subsequent vaccinations within 2 to 6 weeks with the same vaccine strain. ‡Not applicable. * Positive by real-time qPCR / RT-qPCR.
Table 3: Results from multivariable regressions for the 200 FCV-suspect and the 100 healthy cats. Only parameters significantly associated with FCV infection are shown.

| Parameter                      | FCV-suspect cats (n = 200) | Healthy cats (n = 100) |
|-------------------------------|-----------------------------|------------------------|
|                               | Odds ratio | Lower 95% CI | Upper 95% CI | Odds ratio | Lower 95% CI | Upper 95% CI |
| Intact reproductive status    | 1.80       | 0.99         | 3.28         | 22.22      | 1.85         | 266.73       |
| Group housing with ≥ 4 cats   | 2.11       | 1.02         | 4.34         | 46.39      | 5.70         | 377.72       |
| M. felis positive*            | 1.75       | 0.97         | 3.14         |            |              |              |

*Based on the stepwise regression with all predictors, additionally outdoor access was found to be a risk factor for FCV infection. CI = Confidence interval. * Positive by real-time qPCR.
Table 4: Association of clinical signs with FCV infection in the 200 FCV-suspect cats. Significant associations are shown in bold.

| Clinical signs          | Number of FCV-suspect cats (n = 200) | Number of FCV-positive cats (n = 89) | Number of FCV-negative cats (n = 111) | Odds ratios | Lower 95% CI | Upper 95% CI |
|-------------------------|--------------------------------------|--------------------------------------|---------------------------------------|-------------|--------------|--------------|
| Gingivitis              | 103                                  | 62                                   | 41                                    | 3.89        | 2.08         | 7.43         |
| Stomatitis              | 59                                   | 43                                   | 16                                    | 5.50        | 2.71         | 11.64        |
| Caudal stomatitis       | 61                                   | 40                                   | 21                                    | 3.48        | 1.78         | 6.95         |
| Salivation              | 38                                   | 30                                   | 8                                     | 6.48        | 2.69         | 17.47        |
| Oral ulceration         | 23                                   | 18                                   | 5                                     | 5.33        | 1.80         | 19.22        |
| Lingual ulceration      | 20                                   | 15                                   | 5                                     | 4.27        | 1.40         | 15.67        |
| Nasal discharge         | 112                                  | 38                                   | 74                                    | 0.37        | 0.20         | 0.69         |
| Ocular discharge        | 102                                  | 34                                   | 68                                    | 0.39        | 0.21         | 0.72         |
| Sneezing                | 84                                   | 27                                   | 57                                    | 0.41        | 0.22         | 0.77         |
| Keratitis               | 10                                   | 3                                    | 7                                     | 0.52        | 0.08         | 2.36         |
| Conjunctivitis          | 93                                   | 39                                   | 54                                    | 0.82        | 0.45         | 1.50         |
| Anorexia                | 49                                   | 23                                   | 26                                    | 1.14        | 0.56         | 2.29         |
| Apathy                  | 47                                   | 21                                   | 26                                    | 1.01        | 0.49         | 2.05         |
| Elevated body temperature | 29                              | 14                                   | 15                                    | 1.19        | 0.50         | 2.84         |
| Lameness                | 7                                    | 5                                    | 2                                     | 3.23        | 0.51         | 34.67        |
| Skin ulcerations        | 6                                    | 4                                    | 2                                     | 2.55        | 0.36         | 28.85        |
| Joint swelling          | 2                                    | 2                                    | 0                                     | 6.37        | 0.30         | 134.5        |
| Cutaneous edema         | 2                                    | 1                                    | 1                                     | 1.25        | 0.08         | 20.28        |

* CI = Confidence interval.
Figures

Figure 1: Map of Switzerland depicting the origin of the 300 cats enrolled in the study.
Figure 2: Comparison of FCV loads in the swab/cytobrush samples from FCV-suspect cats and the healthy cats.
**Figure legends**

**Figure 1: Map of Switzerland depicting the origin of the 300 cats enrolled in the study.** The numbers listed give the number of cats per canton: a) FCV-suspect/healthy cats; b) FCV-positive/all cats. Basel-Landschaft and Basel-Stadt are listed as a single canton. Maps were produced using QGIS [51].

**Figure 2: Comparison of FCV loads in the swab/cytobrush samples from FCV-suspect cats and the healthy cats.** Loads are given as CT values from the real-time RT-qPCR S1 assay and are depicted as boxplots. A low CT value corresponds to a high load. Of note, the measurements are semi-quantitative because of the collection procedure (cytobrushes and swabs).
Additional files

**Additional file 1: Number of cats PCR-positive for URTD-associated pathogens and co-infections thereof.** The 200 FCV-suspect and 100 healthy cats originated from 19 different cantons in Switzerland.

| (RT-) qPCR-positive for | Number of cats |
|------------------------|---------------|
|                        | FCV-suspect cats (n = 200) | Healthy cats (n = 100) |
| FCV | M. felis | FHV-1 | C. felis | B. bronchiseptica | |
| +  | +  | +  | +  | +  | 0  | 0  |
| +  | +  | +  | +  | -  | 1  | 0  |
| +  | +  | +  | -  | +  | 0  | 0  |
| +  | +  | -  | +  | +  | 11 | 0  |
| +  | +  | -  | +  | -  | 1  | 1  |
| +  | -  | +  | +  | -  | 2  | 0  |
| +  | -  | -  | -  | -  | 34 | 4  |
| +  | -  | -  | -  | +  | 0  | 0  |
| +  | -  | -  | -  | -  | 0  | 0  |
| +  | -  | -  | +  | +  | 4  | 0  |
| +  | -  | -  | +  | -  | 0  | 0  |
| +  | -  | -  | +  | -  | 2  | 0  |
| +  | -  | -  | +  | -  | 0  | 1  |
| +  | -  | -  | -  | -  | 32* | 2  |
| -  | +  | +  | +  | +  | 0  | 0  |
| -  | +  | +  | +  | -  | 0  | 0  |
| -  | +  | +  | -  | +  | 1  | 0  |
| -  | +  | +  | -  | -  | 10 | 8  |
| -  | +  | -  | +  | +  | 0  | 0  |
| -  | +  | -  | +  | -  | 6  | 0  |
| -  | +  | -  | -  | +  | 0  | 0  |
| -  | +  | -  | -  | -  | 27 | 18 |
| -  | -  | -  | -  | -  | 0  | 0  |
| -  | -  | -  | -  | +  | 1  | 0  |
| -  | -  | -  | -  | +  | 2  | 0  |
| -  | -  | -  | -  | +  | 9** | 1  |
| -  | -  | -  | -  | +  | 1  | 0  |
| -  | -  | -  | -  | -  | 3  | 0  |
| -  | -  | -  | -  | +  | 1  | 1  |
| -  | -  | -  | -  | -  | 51 | 64 |

* Contains two FCV-suspect cats, which could not be tested for *B. bronchiseptica* and *M. felis* because of a lack of material. ** Contains one FCV-suspect cat, which could not be tested for *B. bronchiseptica* and *M. felis* because of a lack of material.
**Additional file 2: Frequency of FCV-positive and FCV-negative cats according to number of cats housed per group.** a) 200 FCV-suspect cats; b) 100 healthy cats. FCV-pos./neg. = FCV-positive/negative in FCV real-time RT-PCR. Number of cats = 1: single cats. The numbers in the bars represent the absolute numbers of cats in the respective category.
Additional file 3: Details on missing values, univariable regressions with complete case and imputed data sets.

| Parameter                                      | FCV-suspect  | FCV-suspect, complete | FCV-suspect, imputed | Healthy  | Healthy, complete | Healthy, imputed |
|------------------------------------------------|--------------|-----------------------|----------------------|----------|------------------|------------------|
|                                                 | (n = 200)    | (n = 168)             | (n = 200)            | (n = 100)| (n = 88)         | (n = 100)         |
| Age                                            | 0.12         | 0.03                  | 0.12                 | 0.70     | 1                | 0.76             | 0.71             |
| Sex                                            | 0.38         | 0.42                  | 0.38                 | 0.51     | -                | 0.45             | 0.51             |
| Intact reproductive status                     | 0.02         | 0.03                  | 0.02                 | 0.02     | -                | 0.01             | 0.02             |
| Pedigree                                       | 0.87         | 0.98                  | 0.87                 | 0.28     | -                | 0.35             | 0.28             |
| Multi-cat household                            | 0.09         | 6                     | 0.11                 | 0.08     | 0.17             | 0.17             | 0.17             |
| Group housing with ≥ 4 cats                    | 0.008        | 6                     | 0.009                | <0.001   | 4                | <0.001           | <0.001           |
| Outdoor access                                 | 0.19         | 1                     | 0.17                 | 0.17     | 0.23             | -                | 0.387            | 0.23             |
| Vaccinated                                     | 0.03         | 8                     | 0.03                 | 0.029    | 0.57             | 2                | 0.67             | 0.55             |
| Primary Immunization ‡                         | 0.03         | 18                    | 0.04                 | 0.039    | 0.83             | 8                | 1.00             | 0.86             |
| Immunosuppressive therapy                      | 0.40         | -                     | 0.90                 | 0.399    | 0.995            | -                | 1.00             | 1.00             |
| Antibiotic therapy                             | 0.26         | -                     | 0.32                 | 0.256    | 0.99             | -                | 0.99             | 0.99             |
| Antivirale Therapy                             | 0.51         | 1                     | 0.52                 | NA†      | NA†              | NA†              | NA†              | NA†              |
| FHV-1 positive*                                | 0.77         | -                     | 0.82                 | 0.776    | 0.99             | -                | 0.99             | 0.99             |
| C. felis positive*                             | 0.27         | -                     | 0.43                 | 0.27     | 0.99             | -                | 0.99             | 0.99             |
| B. bronchiseptica positive*                   | 0.74         | 3                     | 0.58                 | 0.99     | -                | 0.99             | 0.99             | 0.99             |
| M. felis positive*                             | 0.02         | 3                     | 0.13                 | 0.019    | 0.06             | -                | 0.07             | 0.06             |

‡ Primary immunization defined as two subsequent vaccinations within 2 to 6 weeks with the same vaccine strain. † Not applicable. * Positive by PCR / RT-PCR.
Acknowledgments

First of all, I thank Prof. Dr. med. vet. Regina Hofmann-Lehmann for giving me the opportunity to work in her group and for her great support throughout the study.

I also thank Prof. Dr. med. vet. Felicitas Boretti for reading and rating my thesis.

I thank my team, especially Dr. M. Meli and Dr. B. Willi for their professional input and patience, E. Gönczi, S. Nesina, T. Meili and C. Asquith for their support in the laboratory and Dr. A. Dreyfus for her dedicated help and patience in working out the statistics with me.

Last but not least, I thank my family and S. Widmer for supporting me during this time.